Incyte company profile

INCY · NASDAQ · USD

Compare Incyte
$119.09Change from previous close: −0.98%Absolute change: −$1.18

Close · November 17, 2026

Company profile

Incyte has 2,844 employees and is headquartered in Wilmington, United States.

JAKAFI, ICLUSIG, MONJUVI, NIKTIMVO, PEMAZYRE and ZYNYZ are the Incyte Corporation medicines most widely known, and the company discovers, develops and commercializes therapeutics. Its marketed products treat myelofibrosis, polycythemia vera, chronic myeloid leukemia, diffuse large B-cell lymphoma and Merkel cell carcinoma, while clinical-stage candidates target ovarian cancer, atopic dermatitis, hidradenitis suppurativa and vitiligo. Products are sold to specialty and retail pharmacies, hospital pharmacies and distributors in the United States, Europe, Canada and Japan.

In the fiscal year ended December 2025, Incyte reported revenue of $5.1 billion, up 21.2% from the previous year, and net income of $1.3 billion. The United States accounted for 93.4% of revenue and Europe for 6.3%. The company had 2,844 employees and is headquartered in Wilmington, Delaware, where it was incorporated in 1991. It was formerly known as Incyte Genomics Inc and took its current name in March 2003.

Company facts

Industry
Biotechnology
Headquarters
1801 Augustine Cut-Off, 19803, Wilmington
Employees
2,844
Chief executive
William Meury
Founded
1991
Fiscal year
January - December
Listing
INCY · NASDAQ
Indices
S&P 500
Currency
USD
ISIN
US45337C1027
Website
incyte.com

Incyte and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
IncyteINCYUnited States$24.36B2,84432.2%61.0
Alnylam PharmaceuticalsALNYUnited States$22.11B2,50019.5%8.34
InsmedINSMUnited States$26.96B1,664-41.7%—
BioNTechBNTXUnited States$21.22B7,807-55.4%—
Roivant SciencesROIVUnited States$28.64B721-3,226.3%—
Ascendis PharmaASNDUnited States$18.06B1,18930.9%18.1

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Incyte with its competitors